Oberland Biotech Secures CHF 2.5 Million Seed Funding to Advance Biotechnology and Nutritional Food Innovation
核心洞察
Oberland Biotech GmbH (搜索) completed a CHF 2.5 million seed funding round through a convertible instrument, supported by 999 Family Office Pte. Ltd (搜索).
The Swiss biotechnology and nutritional food company plans to use the funding for product development, international expansion, recruitment, and marketing growth.
The company focuses on trading, selling, and exporting nutritional supplements and food products internationally while engaging in strategic biotechnology collaborations.
Swiss biotechnology and nutritional food company Oberland Biotech GmbH (搜索) announced the successful completion of a CHF 2.5 million seed funding round through a convertible instrument on May 1, 2026. The funding round was supported by 999 Family Office Pte. Ltd (搜索), acting under the supervision of its lead investor.
Funding Allocation and Strategic Objectives
The new financing will enable Oberland Biotech to accelerate development across key strategic areas, including product development, international expansion, recruitment, and marketing and sales growth. The company operates internationally, focusing on the trade, sale, and export of nutritional supplements and food products across Switzerland and international markets.
Oberland Biotech also engages in strategic collaborations, establishes subsidiaries and branches globally, and participates in projects within the food, nutrition, and biotechnology sectors. The company maintains a flexible structure designed to support long-term global growth.
Global Expansion Plans
The company intends to strengthen its global presence, with particular focus on the United States and Asian markets, while continuing to build scalable operations in the broader international biotechnology and nutrition ecosystem.
"This funding marks an important milestone for Oberland Biotech as we accelerate our mission to develop and scale innovative solutions in the food and biotechnology sector," said Phillip Josef Jancer, CEO and Founder of Oberland Biotech GmbH (搜索). "With the support of our investor, we are well positioned to expand internationally and strengthen our product pipeline."
Investment Partnership
Jancer expressed gratitude to the investment team, stating: "I would also like to sincerely thank the entire team at 999 Family Office Pte. Ltd (搜索), and in particular Mr. Raghun Kataria, their CFO, for their trust, support, and guidance throughout this process."
999 Family Office Pte. Ltd (搜索) is described as an investment family office active in supporting innovative companies across multiple sectors. The partnership represents a strategic alignment between the family office's investment approach and Oberland Biotech's growth objectives in the biotechnology and nutritional food sectors.
Company Profile
Oberland Biotech GmbH (搜索) operates as a biotechnology and food-focused company engaged in the international trade, sale, and export of nutritional supplements and food products. The company develops and participates in projects within the food, nutrition, and biotechnology sectors, positioning itself within the growing intersection of biotechnology innovation and nutritional science.